AngioDynamics, Inc. — Form 10-Q summary
Business context and period: Medical technology company selling devices for vascular access, peripheral vascular disease, oncology and surgical applications. This filing covers the quarter and six months ended November 30, 2022 (fiscal Q2 and first half of fiscal 2023). The company began reporting two segments, Med Tech and Med Device, in fiscal 2023 as part of its shift toward a more focused medical technology business.
Financial performance
| Metric | Three months ended Nov. 30, 2022 | Six months ended Nov. 30, 2022 |
|---|---|---|
| Net sales | $85.4 million, up 9.1% | $167.0 million, up 7.5% |
| Gross profit / margin | $45.1 million / 52.8%, versus 51.8% | $87.4 million / 52.3%, versus 52.0% |
| Operating loss | $8.1 million | $21.4 million |
| Net loss | $8.5 million; $0.21 per diluted share | $21.5 million; $0.55 per diluted share |
| Cash flow from operations | Six-month use of $17.2 million, versus $7.0 million used in the prior-year period |
Segments: Quarterly Med Tech sales rose 29.7% to $24.5 million, while Med Device sales rose 2.6% to $60.9 million. Med Tech gross margin fell to 63.7% from 66.6%; Med Device margin improved to 48.4% from 47.1%.
Balance sheet and liquidity at Nov. 30: Cash was $29.9 million; total debt was $50.0 million, comprising $25.0 million drawn on a $75.0 million revolving facility and $25.0 million on a $30.0 million delayed-draw term loan. The debt carried a 5.59% interest rate. Current assets were $158.8 million and current liabilities $73.6 million. Management said cash and credit availability were expected to meet anticipated needs for at least 12 months; the company was in compliance with its debt covenants.
Changes, outlook and risks
- Sales growth was led by Auryon and NanoKnife; Med Tech growth was partly offset by weaker thrombus-management sales in the quarter. Med Device growth reflected Core, Dialysis, Ports and Microwave products, partly offset by vascular-access backlog and lower oncology procedure volumes.
- Net loss widened year over year in the six-month period. Operating cash use increased, with inventory up $11.8 million and unfavorable movements in receivables, prepaids, payables and accrued liabilities contributing to working-capital use.
- Management cited pricing and product mix pressures, inflation in materials, labor shortages, freight costs, supply-chain disruption and ongoing COVID-related effects on hospital workflow and oncology procedure volumes. Backlog was $5.0 million at Nov. 30, down $2.1 million from Aug. 31.
- No specific financial guidance was provided in the supplied filing text. Management described its liquidity as sufficient for at least the next 12 months, while noting that future cash acquisitions could require external financing.
- Unusual costs included a $3.5 million payment to the Israeli Innovation Authority to settle an obligation related to Auryon development funding, manufacturing relocation costs, and litigation expenses. Acquisition earn-out liabilities totaled $18.8 million; the company recorded a $1.6 million quarterly expense from changes in their fair value.
- In a long-running Bard patent case, a jury found certain port products infringed certain claims in November 2022; damages, equitable issues and patent-eligibility issues remained unresolved, and the company had not accrued a loss because it said the outcome was not yet probable and reasonably estimable. In a separate antitrust action brought by AngioDynamics, a jury found in October 2022 that Bard did not restrain competition.
- Other risks include litigation and product liability, regulatory and clinical outcomes, competition, foreign exchange and floating-rate debt exposure. The company maintained a valuation allowance on certain deferred tax assets due to its lack of sustained profitability. It reported no material change to previously disclosed risk factors.
Facts investors should verify
- Subsequent developments in the Bard patent litigation, including damages, court rulings, appeals and any potential financial exposure.
- Whether Med Tech growth can continue and whether its gross-margin decline reverses; also track Med Device backlog and procedure-volume trends.
- Cash conversion, inventory levels and operating cash use, given the larger first-half cash outflow.
- Debt availability, interest costs and ongoing compliance with leverage and fixed-charge coverage covenants.
- Effects of inflation, labor and supply constraints, litigation costs, and the deferred-tax valuation allowance on future results.